Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update
Autor: | Maurizio Guida, Francesco Orio, R Rosamilio, Maria Antonietta Castaldi, Carmine Selleri, Valentina Giudice |
---|---|
Přispěvatelé: | Guida, Maurizio, Castaldi Maria, Antonietta, Rosamilio, Rosa, Giudice, Valentina, Orio, Francesco, Selleri, Carmine |
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Reproductive medicine Graft vs Host Disease Hematopoietic stem cell transplantation Review Malignancy 03 medical and health sciences 0302 clinical medicine Quality of life immune system diseases Pregnancy hemic and lymphatic diseases Obstetrics and Gynaecology Medicine Humans Fertility preservation Intensive care medicine Reproductive health 030219 obstetrics & reproductive medicine business.industry Hematopoietic Stem Cell Transplantation Obstetrics and Gynecology Disease Management Fertility Preservation Neoplasms Second Primary medicine.disease Female Urogenital Diseases Premature ovarian failure Surgery surgical procedures operative Fertility Oncology 030220 oncology & carcinogenesis Osteoporosis Female business Immunosuppressive Agents |
Zdroj: | Journal of Ovarian Research |
Popis: | In 1963 George Mathe announced to the world that he had cured a patient of leukaemia by means of a bone-marrow transplant. Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT) is considered the most effective treatment of numerous severe haematological diseases. Gynaecological complications in HSCT women represent a serious concern for these patients, but often underestimated by clinicians in the view of Overall Survival. The main gynaecological complications of HSCT are represented by: premature ovarian failure (POF), thrombocytopenia-associated menorrhagia, genital symptoms or sexual problems in course of chronic GVHD (cGVHD), osteoporosis, secondary solid tumours due to immunosuppressive drugs to treat cGVHD and severity of cGVHD, and fertility and pregnancy issues. In particular fertility-related issues are always more relevant for patients, whose life expectation is constantly growing up after HSCT. Thus, taking care of a patient undergoing HSCT should primarily include gynaecological evaluation, even before conditioning regimen or chemotherapy for the underlying malignancy, as, in our opinion, it is of great importance to ensure a complete diagnostic work-up and intervention options to guarantee maximum reproductive health and a better quality of life in HSCT women. The present review aims at describing principal features of the aforementioned gynaecological complications of HSCT, and to define, on the basis of current international literature, a specific protocol for the prevention, diagnosis, management and follow-up of gynaecological complications of both autologous and heterologous transplantation, before and after the procedure. |
Databáze: | OpenAIRE |
Externí odkaz: |